Transgene SA · EURONEXT:TNG

Transgene SA — Investor Presentation (April 2005)

59 slides from Transgene SA's investor presentation, April 2005

  1. Slide 1: Corporate Presentation

    CORPORATE PRESENTATION April 2005 1 transgene

  2. Slide 2: Forward Looking Statement

    Forward Looking Statement This presentation contains forward-looking statements, including statements regarding Transgene’s capital requirements and prospects. Statements that are not historical facts are based on the Company's current expectations, beliefs, estimates, forecasts and assumptions. The

  3. Slide 3: Agenda

    Agenda § INTRODUCTION § TRANSGENE STRATEGIC DIRECTION • New Strategic Direction & Priorities • Latest clinical results & future clinical development § 2004 FINANCIAL RESULTS § CONCLUSION 3 transgene

  4. Slide 4: Key Dates

    Key Dates § 1979 Foundation § 1979 / 1992 : contract-research organization § 1992 Focus on gene transfer technology § 1995 Completion of manufacturing facility (GMP compliant) § 1998 Initial Public Offering on Euronext and Nasdaq (€ 94 M raised) § 2001 Focus on cancer Follow-on : € 63 M raised § 200

  5. Slide 5: Key information

    Key information Headcount: 169 Sites: Strasbourg (France) and Rockville (MA, USA) Mérieux Group Shareholders: (70.3%) (2.2%) Areva Free Float (2.1%) French Muscular Dystrophy (24.9%) Association Financials: Market capitalization: € 88.67 M as of March 31, 2005 10.1 million shares outstanding Cash-on

  6. Slide 6: Management

    Management Dr. Christophe Philippe ARCHINARD Laurence BERTAUD Jean-Yves BONNEFOY Ghislaine GILLERON MERIEUX Chief Executive Director, Human Chief Scientific Officer Director, Legal Affairs & Chairman Officer Ressources Intellectual Property Rémi GLOECKLER Michel HUBERT Elisabeth KEPPI Daniel MALARME

  7. Slide 7: Transgene Strategic Direction

    TRANSGENE STRATEGIC DIRECTION « Establish Transgene as a leader in Therapeutic vaccines in Cancer and Infectious Diseases » 7 transgene

  8. Slide 8: Transgene initially positioned itself on the embryonic Gene Therapy segment

    Transgene initially positioned itself on the embryonic Gene Therapy segment Chemical molecules Recombinant proteins Therapeutic Gene Vaccines therapy Embryonic Emerging Growing Mature Non validated technologies Products in development (no commercial product yet) 8 transgene

  9. Slide 9: Transgene strategic direction is to move downstream towards growing segment

    Transgene strategic direction is to move downstream towards growing segment… Chemical molecules Recombinant proteins Therapeutic Gene Vaccines therapy Nascent Emerging Growing Mature 9 transgene

  10. Slide 10: Focus on therapeutic vaccines in Cancer and Infectious Diseases

    … and focus on therapeutic vaccines in the fields of Cancer and Infectious Diseases Market opportunity Cancer 178 Almost 60% of all biopharmaceutical products are in the field of cancer and Infectious Diseases 68 infectious diseases (large unmet clinical Auto-immunity needs) 26 Neurology 22 Transgen

  11. Slide 11: Rationale for Strategic Direction

    Rationale for Strategic Direction § Large untapped market with no established entrenched players § Therapeutic vaccine is getting market appreciation on the back of post-9/11 vaccine boom and recent clinical trials § Infectious diseases and especially HCV is the best possible candidate to broaden Tr

  12. Slide 12: Short term priorities

    Short term priorities § Focus resources and capabilities towards achieving clinical proof of concept on most promising product and indications § Re-deploy research program to support product strategy ü Development of cancer & infectious disease vaccine candidates ü Broadening Transgene’s technology

  13. Slide 13: Implication of new strategy on Transgene Development Engine

    Implication of new strategy on Transgene Development Engine Research Vaccine Evaluation cGMP Clinical Technology Candidates Immunogenicity Production Trials bricks Preclinical • Immuno-adjuvants In vitro & In vivo Viral vectors • Oncolytic vectors • Oncology Evaluation Indication-specific • Viral ve

  14. Slide 14: Consequences on clinical plan

    Consequences on clinical plan MARKET REALITY RECOMMENDATION § The number of cancer vaccines in phase Streamline portfolio and focus on selected II and III is large. Competitors validating products in order to get significant proof of this therapeutic approach concept on a candidate for a given indic

  15. Slide 15: 2004 Clinical program

    2004 Clinical program Indication Preclinical Phase I Phase II Status (*) MVA-MUC1-IL2 Lung Completed 65 patients Completed MVA-MUC1-IL2 Prostate 40 patients Completed MVA-MUC1-IL2 Kidney 37 patients On-going MVA-HPV-IL2 CIN 2/3 (6 month follow up) 5 patients On-going Ad-IFNγ Cutaneous T-Cell Lymphom

  16. Slide 16: 2005 Clinical Development Plan

    2005 Clinical Development Plan Indication Preclinical Phase I Phase II Next step MVA-MUC1-IL2 Lung Phase IIb MVA-MUC1-IL2 Prostate Suspended MVA-MUC1-IL2 Kidney Suspended MVA-HPV-IL2 CIN 2/3 (6 month follow up) Phase IIb Ad-IFNγ Cutaneous T-Cell Lymphoma (CTCL) Phase II / III Ad-IL2 Malignant Melano

  17. Slide 17: Latest Clinical Results

    Latest Clinical Results 17 transgene

  18. Slide 18: MVA-MUC1-IL2

    MVA-MUC1-IL2 18 transgene

  19. Slide 19: MVA-MUC1-IL2 Product profile

    MVA-MUC1-IL2 Product profile Recombinant MVA (Modified Virus Ankara) ü non-replicative, highly immunogenic Skin poxvirus Immune cells Expressing MUC1 tumor-associated antigen Tumor ü MUC1 is found in most adenocarcinoma Skin Expressing human IL-2 cDNA ü stimulation of specific T-cell response Status

  20. Slide 20: MUC1 expression in NSCLC

    MUC1 expression in NSCLC Associated with poor prognosis MUC1+ cells <25% % overall survival MUC1+ cells > 25% Time (days) § MUC1 protein may have oncogenic activity (Li et al., 2003). § MUC1 attenuates the apoptotic response to oxydative stress (Yin et al., 2003). § MUC1 expression is a marker of tu

  21. Slide 21: MUC1 Expression in Major Cancers

    MUC1 Expression in Major Cancers 90,0% 60,0% 60,0% MUC1+ MUC1+ MUC1+ Breast Lung Prostate 70,0% 80,0% 90,0% MUC1+ MUC1+ MUC1+ Colorectal Stomach Liver (cholangiocarcinoma) 21 transgene

  22. Slide 22: MVA-MUC1-IL2 Clinical Trial Design

    MVA-MUC1-IL2 Clinical Trial Design § Clinical settings and modalities Clinical Stage of Treatment Evaluation settings the disease modalities criteria Lung Stade IIIb/IV Combination with Tumor response cancer non resectable chemotherapy 2 arms Prostate Non-metastatic Monotherapy PSA level cancer PSA

  23. Slide 23: MVA-MUC1-IL2 Phase II interim results

    MVA-MUC1-IL2 Phase II interim results End points reached in NSCLC § Interim Results (February 2005) Arm 1 (TG4010 + chemo) : 35 evaluable patients 13/35 (37%) PR (validated by central reading) 11/35 (31%) SD > 12w 24/35 (68%) Clinical benefit Time to Progression 6.4 months Overall survival > 12 mont

  24. Slide 24: MVA-MUC1-IL2 in NSCLC: Comparison with published clinical studies

    MVA-MUC1-IL2 in NSCLC : Comparaison with published clinical studies using Navelbine / Cisplatine regimen Study % response Study TTP Study Overall survival Gebbia 44 TG4010 + chemo 6.4 m TG4010 + chemo >12 m TG4010 + chemo 37 % Gridelli 5.3 Fossela 10.1 Souquet 34.6 Fossela 5.1 Scagloitti 9.5 Le Chev

  25. Slide 25: Clinical design Phase IIb in NSCLC

    MVA-MUC1-IL2 Clinical design Phase IIb in NSCLC Targeted Intervention: Primary Decision Population: Endpoints to continue RR on phase III: Chemo. TTP +TG4010* Gain in response rate IIIB/IV Secondary higher than 7% MUC1+ Endpoint PS 0 or 1 R OS Gain in 100 patients Median TTP higher than Chemo. 1.5 M

  26. Slide 26: MVA-MUC1-IL2: Prostate Cancer Study

    MVA-MUC1-IL2 : Prostate Cancer Study Patient PSA-DT (Slope calculated) Interim analysis Dec 2004 80 PSA - Doubling Time (months) Pre-Vaccination 70 During Immunotherapy 60 50 40 30 20 10 0 1001 1002 1003 1008 5001 5003 7002 7003 7005 7007 7010 7011 7012 8002 8004 1004 1005 1006 1007 5002 7001 7004 7

  27. Slide 27: MVA-MUC1-IL2: Prostate Cancer Study

    MVA-MUC1-IL2 : Prostate Cancer Study Patient PSA-DT (Slope calculated) Interim analysis Dec 2004 Immunization schedule Weekly 3 weekly Pre-vac. Post-vac. Fold Pre-vac Post-vac Fold change change Mean 4.77 16.40 3.64 5.37 8.24 1.51 Median 4.70 7.10 1.93 5.60 6.50 1.34 P < 0.0001 ü80% of patients incr

  28. Slide 28: MVA-MUC1-IL2 Market potential

    MVA-MUC1-IL2 Market potential PROSTATE Patients with rising PSA after primary treatment (biochemical failure) Population incidence is estimated at 150.000 for Europe and US Metastatic NSCLC First line therapy for metastatic disease in combination with chemotherapy Mortality rate estimated at 350.000

  29. Slide 29: MVA-MUC1-IL2 Future direction

    MVA-MUC1-IL2 Future direction § Proven biological activity by slowing down or stopping the growth of tumour of several origins § Most encouraging results obtained in lung cancer with possible synergy between MVA-MUC1-IL2 and chemotherapy § Final data presentation at ASCO (13-17 May 2005) § Next step

  30. Slide 30: MVA-HPV-IL2

    MVA-HPV-IL2 30 transgene

  31. Slide 31: MVA-HPV-IL2 Product profile

    MVA-HPV-IL2 Product profile Recombinant MVA (Modified Virus Ankara) ü non-replicative, highly immunogenic Skin poxvirus Immune cells Expressing early genes of Human Papilloma Tumor Virus 16 (HPV16) ü CIN (cervical intraepithelial neoplasia) Skin due to HPV: pre-cancerous stage of cervix Cancer ü “HP

  32. Slide 32: MVA-HPV-IL2 Potential product positioning

    MVA-HPV-IL2 Potential product positioning HPV infection Prophylaxis Persistent infection CIN2-3 Late-stage Cervix Cancer Surgery No vaccine No treatment Chemotherapy (conisation) L1 ± L2 E1 ± E2 E7 ± E6 ± E1 E7 ± E6 32 transgene

  33. Slide 33: MVA-HPV-IL2 Clinical Trial Design (completed Phase II)

    MVA-HPV-IL2 Clinical Trial Design (completed Phase II) § Multicenter study in France § CIN2/3 in HPV16+ patients § 3 SC injections of TG4001, on Days 1-8-15 § 2 doses tested: 5x105 pfu and 5x107 pfu § Standard treatment (conisation) on Week 6-8 33 transgene

  34. Slide 34: MVA-HPV-IL2 Final results of completed Phase II

    MVA-HPV-IL2 Final results of completed Phase II Summary table of TG4001 dose (pfu) secondary efficacy endpoints 5x105 5x107 Patients treated 14 17 Patients analyzed for efficacy 13 16 Viral clearance 0 4 Partial regression of histology signs 0 5 Reduction of grade (to CIN1) 0 2 Limited extent of his

  35. Slide 35: MVA-HPV-IL2 Clinical Trial Design (Phase IIb)

    MVA-HPV-IL2 Clinical Trial Design (Phase IIb) CIN2/3 in HPV 16 + patients Study design ü Open-label, 5x107 pfu ü 18 CIN2/3 patients Treatment plan ü Up to 6-month assessment period to study efficacy ü Follow-up every 2 months : Cytology + virology + colposcopy ± biopsy ü Responder (no need of conisa

  36. Slide 36: Incidence: HPV-related diseases

    Incidence: HPV-related diseases Europe/US HPV16 Worldwide Cervix cancer 80,000 50% 470,000 CIN2/3 700,000 50% 1,400,000 CIN1 1,400,000 20% 14,000,000 Silent infection 14,000,000 20% 420,000,000 36 transgene

  37. Slide 37: Ad-IFNγ

    Ad-IFNγ 37 transgene

  38. Slide 38: Ad-IFNγ Product profile

    Ad-IFNγ Product profile Recombinant adenovirus vector containing the sequence coding for the human IFN-g cDNA Mechanism of action ü Direct action on tumor cells: antiproliferative, induction of apoptosis ü Indirect actions on tumors: immune stimulation, antiangiogenic activities ü IFN-g is a major T

  39. Slide 39: Ad-IFNγ Clinical Trial Design

    Ad-IFNγ Clinical Trial Design Phase I/II : Primary Cutaneous Lymphoma ü Study design Dose escalation 3 dose levels 3.109 tp → 3.1011 tp 3 patients / dose level (Phase I) + 9 patients at highest dose + up to 18 patients (Phase I / II) ü Treatment plan Intra-tumoral administration Weekly injections (D

  40. Slide 40: Ad-IFNγ Efficacy results

    Ad-IFNγ Efficacy results § Interim data first 20 patients ü Clinical responses observed locally 7 CR and 3 PR out of 18 evaluable patients (56%) ü Distant clinical responses : 2 CR – 1 PR out of 12 evaluable patients ü Overall response rate (53%) 40 transgene

  41. Slide 41: Ad-IFNγ Market potential

    Ad-IFNγ Market potential CTCL Patients with limited number of lesions and refractory / relapsing to at least two lines of standard therapy Population incidence is estimated at 38.000 in Europe and US Hepato Cellular Carcinoma Worldwide incidence is estimated at 600.000 Population incidence is estima

  42. Slide 42: Ad-IFNγ Future direction

    Ad-IFNγ Future direction § Clinical development Cutaneous Lymphoma: ü Phase II / III study (Q1 06 – Q1 08) in CTCL patients ü Placebo controlled – 2 step study – 75 patients § Regulatory strategy : ü U.S.: • IND preparation and filing in process to be followed by SPA • Orphan drug designation submis

  43. Slide 43: MVA HCV

    MVA HCV 43 transgene

  44. Slide 44: MVA-HCV Product design

    MVA-HCV Product design § Genomic organization of HCV (RNA of 9.6 Kb) 5‘ NON CODING 3‘ NON CODING REGION STRUCTURAL REGION NON- NON-STRUCTURAL REGION REGION NS4A P7 C E1 E2 NS2 NS3 NS4 B NS5 A NS5 B UUU 7 CORE GLYCOPROTEINS PROTEASE/HELICASE RNA POLYMERASE § Recombinant MVA (Modified Virus Ankara) ex

  45. Slide 45: MVA-HCV Clinical program

    MVA-HCV Clinical program Study design § MVA-HCV alone § Start Phase I / II in § Dose-escalating safety study in the USA (Q1 2006) chronically infected HCV patients Phase I ü Non-responder to reference treatment ü Treatment-naïve patients § Preparation of different « Prime- On-going boost » combinati

  46. Slide 46: MVA-HCV Market potential

    MVA-HCV Market potential § 170 M people world-wide are infected by HCV, including 12 M chronically infected in the USA and Europe. § 10,000 to 12,000 deaths/year in the USA, predicted to increase dramatically in the next two decades § Leading indication for liver transplant § 50% pts infected with t

  47. Slide 47: Muscular Dystrophy

    Muscular Dystrophy 47 transgene

  48. Slide 48: Myodys

    Myodys® § Fully-financed by the French Association against Muscular Dystrophy § First ever gene based trial in Duchenne Muscular Dystrophy § Phase I trial completed in 2003. Objectives fulfiled: ü expression of normal dystrophin detected in the injected muscle ü no immune rejection § On-going develo

  49. Slide 49: 2004 Financial Results

    2004 FINANCIAL RESULTS 49 transgene

  50. Slide 50: Statement of Operations

    Statement of Operations US GAAP; in € million ; unaudited 2004 2003 Revenues 2.5 2.5 Operating expenses (24.2) (24.5) R&D (20.0) (20.3) G&A (4.2) (4.3) Restructuring - 0.1 Loss from operations (21.7) (22.0) Interest income 0.5 1.1 Income tax benefit 0.7 - Net loss (20.5) (20.9) 50 transgene

  51. Slide 51: Revenues

    Revenues US GAAP; in million €; unaudited 2004 2003 Variation A.F.M. 1.1 1.2 (0.1) Contracts 0.7 * 0.3 + 0.4 Licenses 0.7 1.0 (0.3) 2.5 2.5 - * Productions for Eurovac/Karolinska during first half 2004 not included 51 transgene

  52. Slide 52: 2004 Cash expenditures

    2004 Cash expenditures US GAAP; in million €; unaudited 40 + 0,5 + 0,2 + 2,8 35 30 - 22,6 25 20 34,9 - 0,7 - 0,5 15 10 14,7 5 0 Cash & Cash Revenues R&D tax Interest Income Operating Capital Financing Cash & Cash equivalents credit refund expenses expenditures equivalents at 31.12.2003 excl. at 31.1

  53. Slide 53: 2004 Net Cash expenditures

    2004 Net Cash expenditures US GAAP; in € millions; unaudited 2004 2003 Net cash expenditures (20.3) (19.6) The € 0,7 M additional cash expenditures is mostly due to: M€ ü R&D tax credit refund (ø) - 0.6 üInterest income(ø) - 0.6 üOperating expenditures (ø) 0.3 üCapital expenditures(ø) 0.3 - 0.6 53 t

  54. Slide 54: Conclusion

    CONCLUSION 54 transgene

  55. Slide 55: 2005 Clinical Development Plan

    2005 Clinical Development Plan Indication Preclinical Phase I Phase II Next step MVA-MUC1-IL2 Lung Phase IIb MVA-MUC1-IL2 Prostate Suspended MVA-MUC1-IL2 Kidney Suspended MVA-HPV-IL2 CIN 2/3 (6 month follow up) Phase II Ad-IFNγ Cutaneous T-Cell Lymphoma (CTCL) Phase II / III Ad-IL2 Malignant Melanom

  56. Slide 56: Next Milestones and Newsflow

    Next Milestones and Newsflow PRODUCT INDICATION MILESTONE DATE Asco presentation of results for Lung & Prostate Q2 2005 MVA-MUC1-IL2 NSCLC / Lung Start of Phase IIb trial Q4 2005 MVA-HPV-IL2 CIN 2/3 Results on Phase II trial Q4 2005 Feedback on IND (and SPA) review Q2 2005 Ad-IFNg CTCL Start of Phas

  57. Slide 57: Transgene's technology value: potential for growth

    Transgene‘s technology value: potential for growth Estimated technology values as of March 31, 2005 450 419 389 400 350 300 250 225 185 200 179 148 150 150 117 98 100 100 63 70 50 28 15 17 11 0 Epim m une Virax Aphton Vic al G envec Transgene O xford Biom ira Cancervax D endreon Interc ell Cell Cori

  58. Slide 58: Investment case

    Investment case § Clinical pipeline with 3 phase II in active development § Products with large market potential aiming at fullfilling large unmet medical needs § Focused strategy in therapeutic vaccine field, leading to rich newsflow in 2005 § Large reservoir of opportunities (internal product cand

  59. Slide 59: Transgene contact details

    Transgene 11 rue de Molsheim 67082 Strasbourg Cedex France Contact : communication@transgene.fr Tel : +33-(0)3.88.27.91.02 Web Site : www.transgene.fr 59 transgene

Transgene — Investor Presentation (April 2005) on 6ix